Oct 10th 2012 - Edison Investment Research today published a report on Synta Pharmaceuticals entitled "Ganetespib Plan Takes Shape". In summary, the report says:
Synta looks set to start the Phase III stage of the GALAXY study of ganetespib in second-line non-small cell lung cancer (NSCLC) with broad entry criteria, after interim data suggested more consistent activity than was previously expected across key sub-groups. Synta has confirmed that the Phase III stage will enrol around 500 patients. A decision to enrol all comers with adenocarcinoma, if confirmed, is a potentially significant value-generating event for Synta, as our valuation currently assumes it will target a substantial minority of patients (ie 25-40%).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »